Intensive Lifestyle Changes Do Raise Odds of T2DM Remission

Although overall remission rates are modest

TUESDAY, Dec. 18 (HealthDay News) -- For overweight adults, an intensive lifestyle intervention (ILI) is associated with a greater likelihood of remission compared with diabetes support and education (DSE), although the absolute remission rates are modest, according to a study published in the Dec. 19 issue of the Journal of the American Medical Association.

Edward W. Gregg, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues conducted an ancillary observational analysis of a four-year randomized controlled trial comparing ILI (2,241 participants) with a DSE control condition (2,262 participants) among U.S. adults with type 2 diabetes and with a body mass index of 25 kg/m² or higher.

The researchers found that participants in the ILI lost significantly more weight and had significantly greater fitness increases than the DSE group at years one and four. Compared with the DSE group, participants in the ILI group were significantly more likely to experience complete or partial remission, defined as a transition from meeting the criteria for diabetes to a prediabetes and non-diabetes level of glycemia (11.5 percent during the first year; 7.3 percent at year four; compared with 2 percent at each time point for controls). Continuous, sustained remission was seen for at least two, three, and four years for 9.2, 6.4, and 3.5 percent of participants, respectively, in the ILI group, compared with less than 2, 1.3, and 0.5 percent, respectively, for the DSE group.

"In these exploratory analyses of overweight adults, an intensive lifestyle intervention was associated with a greater likelihood of partial remission of type 2 diabetes compared with diabetes support and education," the authors write. "However, the absolute remission rates were modest."

Two authors disclosed financial ties to the pharmaceutical and biotechnology industries. Look AHEAD was sponsored by several companies in the pharmaceutical and nutrition industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by